Managing Bleeding with Nexplanon
For Nexplanon users experiencing abnormal bleeding, first rule out pregnancy and underlying gynecologic pathology (STDs, medication interactions, uterine conditions), then offer NSAIDs (mefenamic acid 500mg TID for 5-7 days) as first-line treatment, or combined oral contraceptives/estrogen (10-20 days) for heavy/prolonged bleeding if the patient desires treatment. 1
Initial Evaluation
When a Nexplanon user presents with bleeding concerns, your evaluation should focus on:
- Pregnancy testing - Rule this out first, especially if bleeding pattern changes abruptly 1, 2
- STD screening (chlamydia/gonorrhea) - Active infection can cause abnormal bleeding 1
- Medication review - Check for drug interactions affecting bleeding 1
- Pelvic examination - Assess for structural pathology (polyps, fibroids) if clinically indicated 1
The FDA label emphasizes that abnormal bleeding should be evaluated to exclude pathologic conditions or pregnancy, particularly if persistent or recurrent 2.
Understanding Normal Bleeding Patterns
Before treating, recognize that bleeding changes are extremely common and generally not harmful 1, 2. The FDA data shows:
- 22% experience amenorrhea
- 34% have infrequent spotting
- 18% have prolonged bleeding
- 7% have frequent bleeding
The bleeding pattern in the first 3 months broadly predicts future patterns 2. This counseling point is critical - many women discontinue unnecessarily without understanding this is expected.
Treatment Algorithm
For Light Spotting or Irregular Bleeding
If no underlying pathology is found and the patient wants treatment:
- NSAIDs for 5-7 days during bleeding episodes 1
For Heavy or Prolonged Bleeding
Treatment options during bleeding days:
NSAIDs (5-7 days) - Same as above 1
Hormonal treatment (if medically eligible):
Norethisterone acetate 10mg daily - A 2025 RCT showed 86.7% achieved bleeding cessation within 7 days vs 48.9% with placebo, though bleeding recurred faster (5 vs 10.5 days) 4
Evidence Quality Considerations
The 2013 CDC guidelines 1 provide the framework, but newer research offers important nuances:
- COCs are more effective than NSAIDs for managing implant bleeding 3
- Tranexamic acid does NOT work - a 2026 RCT showed no benefit 5
- Mefenamic acid and celecoxib have the best NSAID evidence 1, 6
- Ulipristal acetate and tamoxifen showed promise in systematic reviews, but are not standard practice 6
When Treatment Fails
If bleeding persists and is unacceptable to the patient:
- Counsel on alternative contraceptive methods
- Offer method change 1
Irregular bleeding was the single most common reason for discontinuation (10.8%) in clinical trials 2. Don't let patients suffer through unacceptable bleeding - method switching is a valid option.
Special Situations
Amenorrhea
- No treatment needed - provide reassurance 1
- If pattern changes abruptly to amenorrhea, rule out pregnancy 1
- If unacceptable to patient, offer alternative method 1
Persistent/Recurrent Bleeding
Rule out malignancy if bleeding is undiagnosed, persistent, or recurrent 2. Consider:
- Endometrial sampling if risk factors present
- Imaging (transvaginal ultrasound, MRI if needed) 7
Critical Pitfalls to Avoid
- Don't use aspirin or vitamin E - no evidence of efficacy 1
- Don't assume ibuprofen works - inconsistent evidence despite common use 1
- Don't forget to counsel BEFORE insertion - enhanced counseling about expected bleeding patterns reduces discontinuation 1
- Don't miss pregnancy or pathology - always evaluate before treating as "normal" implant bleeding 1, 2
- Don't continue ineffective treatment - if bleeding persists despite treatment, offer method change rather than prolonging dissatisfaction 1